Figure 4

Effects of exogenous CART treatment on memory impairments and Aβ plaque load in APP/PS1 mice.

(a) CART treatment of APP/PS1 transgenic mice significantly lowered the latency to escape a submerged platform in the Morris water maze test at 8 months of age. All data are expressed as mean ± SEM, n = 15 mice/group, *p < 0.05, **p < 0.01 versus B6 control mice. ^#p < 0.05 versus APP/PS1 transgenic mice without CART treatment. CART-treated APP/PS1 mice also made higher numbers of passes over the submerged platform (b) and spent more time in the target quadrant (c) compared to APP/PS1 mice without CART treatment. All data are expressed as mean ± SEM, n = 15 mice/group, **p < 0.01 versus B6 control mice, ^##p < 0.01 versus APP/PS1 transgenic mice without CART treatment. (d) Aβ-immunoreactive plaques in 8-month-old APP/PS1 transgenic mice in the absence or presence of CART, Scale bar: 100 μm. Counts of total Aβ plaque numbers (e) and Aβ plaque load (f) in the cortex and hippocampus of 8-month-old APP/PS1 mice (6–12 sections/mouse). All values are expressed as mean ± SEM, n = 3 mice/group.